Home' Australian Pharmacist : Australian Pharmacist May 2012 Contents pre-existing cardiovascular disease; epileptic disorder or predisposition to convulsions; patients
on long-term high dose opioid treatment switching to TARGIN® tablets; chronic non-cancer pain;
prior history of substance abuse. Not recommended in patients with galactose intolerance,
Lapp lactase deficiency or glucose-galactose malabsorption; for the treatment of withdrawal
symptoms; patients with cancer associated with peritoneal carcinomatosis or sub-occlusive
syndrome in advanced stages of digestive and pelvic cancers. To lerance and physical
dependence tend to develop upon repeated administration. Withdraw gradually. Parenteral or
intranasal abuse in opioid-dependent individuals is expected to produce marked withdrawal
symptoms. Parenteral venous administration may be fatal. Reduce dosage to ¹G3 to ¹G2 of the
usual dose in elderly patients who are infirm or debilitated and in patients with renal failure or
mild hepatic impairment. May impair ability to drive and operate machinery. May produce
positive results in sports agency drug testing procedures. Not recommended for immediate
pre-operative use and post-operative for 24 hours after surgery. Do not use within 24 hours
of cordotomy or other pain-relieving surgery. INTERACTIONS Anticholinergic agents,
antihypertensives, CNS depressants (antidepressants, sedatives, hypnotics, general
anaesthetics, phenothiazines or other tranquilizers, alcohol, other opioids, anti-histamines,
anti-emetics, neuroleptics etc), coumarin derivatives, metoclopramide, non-selective
MAOIs or within 14 days of stopping treatment (caution is advised with selective MAOIs),
neuromuscular blocking agents, opioid agonist analgesics and mixed agonist/antagonist
analgesics, drugs that affect the P450 enzyme system (CYP3A4, CYP2D6). ADVERSE
EFFECTS Typical of full opioid agonists and tend to reduce with time. Common side effects
(incidence ≥1%) include agitation, anorexia, asthenic conditions, abdominal pain,
bronchospasm, chills, constipation, diarrhoea, dizziness, drug withdrawal syndrome, dry mouth,
dyspepsia, faintness, fever, gastritis, headache, hepatic enzymes increased, hiccup, hyperhidrosis,
hypotension, mood changes, muscle spasms, muscle twitching, myalgia, nausea, orthostatic
hypotension, pharyngitis, pruritus, rash, ureteric spasm, urinary abnormalities, urinary tract
infection, vertigo, voice alteration, vomiting. DOSAGE AND ADMINISTRATION Must be swallowed
whole and not broken, chewed or crushed. Taking broken, chewed or crushed TARGIN® tablets
could lead to the rapid release and absorption of a potentially toxic dose of oxycodone
that could be fatal. Adults: Usual starting dose (opioid-naïve patients, or patients with moderate to
severe chronic pain uncontrolled by weaker opioids): one TARGIN® 10/5 mg tablet 12-hourly.
Patients with renal or mild hepatic impairment: one TARGIN® 5/2.5 mg tablet 12-hourly. Titrate
cautiously (every 1--2 days if necessary) to achieve pain relief. Maximum recommended daily dose:
80/40 mg (TARGIN® 40/20 mg tablets 12-hourly).
Children: Not recommended in patients below
12 years of age. TGA APPROVAL DATE 5 March 2010. DATE OF FIRST INCLUSION ON ARTG
12 May 2010. DATE OF MOST RECENT AMENDMENT 28 December 2011. PBS DISPENSED
PRICE 5/2.5mg (28s), $29.37; 10/5mg (28s), $30.67; 20/10mg (28s), $46.85; 40/20mg (28s),
$73.28. REFERENCES: 1. TARGIN® tablets Product Information. December 2011. 2. Meissner W
et al. Eur J Pain 2009;13(1):56--64. 3. Löwenstein O et al. Expert Opin Pharmacother 2009;10(4):
531--543. 4. Löwenstein O et al. BMC Clin Pharmacol 2010;10:12. 5. Sandner-Kiesling A et al.
Int J Clin Pract 2010;64(6):763--774. 6. Simpson K et al. Curr Med Res Opin 2008;24(12):3503--3512.
7. Vondrackova D et al. J Pain 2008;9(12):1144--1154. ®: TARGIN is a Registered Trademark.
Mundipharma Pty Limited ABN 87 081 322 509, 50 Bridge Street, Sydney, NSW 2000.
Tel: 1800 188 009. Saatchi & Saatchi Health MUN0194/AP/CP ORBIS AU-1297 Apr 12.
Now there is an opioid analgesic that relieves pain while helping
to prevent opioid-induced constipation (OIC).1,2 TA RGIN® tablets
provide effective pain relief and help prevent OIC, in a single
formulation.1,2 Patients can now experience the pain relief
expected from controlled release oxycodone but with less
OIC compared with oxycodone alone.1, 3--7
Links Archive Australian Pharmacist June 2012 Australian Pharmacist April 2012 Navigation Previous Page Next Page